Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities.
Scientific Congress Publications
Supported by Bayer Pharmaceuticals
ESC 2026
Pre-randomization NT-proBNP trajectory and outcomes in the VICTOR trial
- In the VICTOR trial, enrolment was enriched using screening N-terminal pro-B-type natriuretic peptide (NT-proBNP) thresholds of 600–6000 ng/L (900–6000 ng/L if in atrial fibrillation [AFib]). However, NT-proBNP levels may have fluctuated between screening and randomisation.
- To evaluate the impact of different NT-proBNP trajectories between screening and randomisation on outcomes in the VICTOR trial.
- In this post hoc analysis of the VICTOR trial, no differences in outcomes were observed across 3 subgroups of NT-proBNP trajectory between screening and randomisation.
© 2026 Bayer. All rights reserved.
Bayer and the Bayer Cross are registered trademarks of Bayer.
Copies of the Bayer Pharmaceuticals supported presentations obtained from this platform are for personal use only and may not be reproduced or distributed without permission from the authors.
Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities, and the presentations are shared in the interest of scientific exchange.
For any questions, please contact Medical Information at https://www.medicalinformation.bayer.com/
PP-GEN-ALL-0014-1
